0001104659-24-030174.txt : 20240301
0001104659-24-030174.hdr.sgml : 20240301
20240301215246
ACCESSION NUMBER: 0001104659-24-030174
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240222
FILED AS OF DATE: 20240301
DATE AS OF CHANGE: 20240301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pla Frederic
CENTRAL INDEX KEY: 0001649167
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40344
FILM NUMBER: 24712709
MAIL ADDRESS:
STREET 1: C/O GENOMIC HEALTH, INC.
STREET 2: 101 GALVESTON DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063-4700
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akoya Biosciences, Inc.
CENTRAL INDEX KEY: 0001711933
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 475586242
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 CAMPUS DRIVE
STREET 2: 6TH FLOOR
CITY: MARLBOROUGH
STATE: MA
ZIP: 01762
BUSINESS PHONE: 855.896.8401
MAIL ADDRESS:
STREET 1: 100 CAMPUS DRIVE
STREET 2: 6TH FLOOR
CITY: MARLBOROUGH
STATE: MA
ZIP: 01762
4
1
tm247817-4_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-02-22
0
0001711933
Akoya Biosciences, Inc.
AKYA
0001649167
Pla Frederic
100 CAMPUS DRIVE, 6TH FLOOR
MARLBOROUGH
MA
01752
0
1
0
0
Chief Operating Officer
0
Common Stock
2024-02-22
4
A
0
35000
0.00
A
105555
D
Common Stock
2024-03-01
4
F
0
2049
6.03
D
103506
D
Common Stock
20000
I
By The Pla Family Trust dtd 8/7/14
Employee Stock Option (Right to Buy)
5.35
2024-02-22
4
A
0
70000
0.00
A
2034-02-22
Common Stock
70000
70000
D
The restricted stock units shall vest in four (4) equal annual installments beginning on March 1, 2025, and annually thereafter until fully vested.
Each restricted stock unit represents a contingent right to receive one share of Akoya Biosciences, Inc. common stock.
Represents shares withheld to cover taxes on a restricted stock unit award previously granted February 23, 2023, which vest in four (4) equal annual installments beginning on March 1, 2024, and annually thereafter until fully vested.
The options shall vest as follows: twenty-five percent (25%) shall vest on February 22, 2025 with the remainder vesting in 36 equal monthly installments beginning on March 22, 2025.
/s/ Frederic Pla, by Brian McKelligon, as Attorney-in-Fact
2024-03-01